Elise Carlson, MD
Rheumatology · Milford, CTNPI 1811971260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Amgen at 24.6% of the total. Reporting peaked in 2019 at $1,167 and has fallen 94.2% since, to $68 in 2024.
Across 97 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$379
- AbbVie$170
- UCB, Inc.$145
- Pfizer$142
- Lilly USA, LLC$137
- Sanofi$102
- plus $462 from 13 others
What the payments were for
- Food & beverage$1,52599%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $379 |
| AbbVie | 8 | $170 |
| UCB, Inc. | 6 | $145 |
| Pfizer | 12 | $142 |
| Lilly USA, LLC | 10 | $137 |
| Sanofi | 3 | $102 |
| Genentech USA, Inc. | 5 | $83 |
| Novartis | 4 | $81 |
| Boehringer Ingelheim | 2 | $49 |
| Merck | 3 | $45 |
| Bristol Myers Squibb | 2 | $35 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Sebela Pharmaceuticals Inc. | 1 | $16 |
| Medexus Pharma, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enbrel$107
How this compares
$1,537 in reported general payments places this provider in the 55th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 70 | $595,508 |
| OtezlaApremilast | 62 | $372,298 |
| Enbrel SureclickEtanercept | 36 | $362,577 |
| Xeljanz XrTofacitinib Citrate | 29 | $333,334 |
| EnbrelEtanercept | 46 | $329,247 |
| OrenciaAbatacept | 56 | $328,534 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $271,120 |
| OrenciaAbatacept/Maltose | 37 | $169,556 |
| TremfyaGuselkumab | 12 | $166,278 |
| Humira(Cf)Adalimumab | 16 | $149,855 |
| RinvoqUpadacitinib | 24 | $149,287 |
| BenlystaBelimumab | 28 | $125,456 |
| Cosentyx Unoready PenSecukinumab | 12 | $89,881 |
| Cosentyx Sensoready PenSecukinumab | 12 | $89,637 |
| XeljanzTofacitinib Citrate | 13 | $73,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel, Prolia | $379 | $729,020124 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $31 | $498,09193 claims |
| AbbVieHumira(Cf), Rinvoq | $170 | $299,14340 claims |
| Johnson & JohnsonTremfya | $20 | $166,27812 claims |
| GSKBenlysta | $21 | $125,45628 claims |
| PfizerXeljanz | $142 | $73,98413 claims |
| UCB, Inc.Cimzia (2 Pack) | $145 | $67,43912 claims |
| Medexus Pharma, Inc.Rasuvo | $14 | $13,91725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Milford
- Julie YipMilford$8K
- Kenneth MillerDanbury$873K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
- James SeiboldFarmington$300K
- Michael SpiegelDanbury$215K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
- Richard RoseffDanbury$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.